E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for Acambis plc > News item
Published on 5/9/2006 in the Prospect News Biotech Daily.

Merrill keeps Acambis at neutral

Merrill Lynch analyst Peter Welford retained Acambis plc at a neutral rating as the company reported a greater-than-expected first-quarter net loss of £11.3 million, or 10.5p per share, compared with the analyst's estimate of £10.4 million, or 9.9p per share. Merrill increased its 2006 forecast to a net loss of £30.3 million from £29.6 million. Shares of the Cambridge, U.K., biotechnology company were up $0.009, or 0.14%, at $6.92 on volume of 15,529 shares versus the three-month running average of 18,058 shares. (Nasdaq: ACAM)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.